Crucell in licensing agreement with Tibotec for PER.C6 cell line

By Angela McDaniels

Seattle, Nov. 23 - Crucell NV said it has signed a non-exclusive license agreement with Tibotec Pharmaceuticals Ltd. for use of Crucell's PER.C6 cell line in virology research.

Under the terms of the agreement, Tibotec will pay an undisclosed research license fee, annual maintenance fees and milestone payments.

Tibotec, based in Little Island, Ireland, is a pharmaceutical company that develops HIV/AIDS drugs and anti-infectives.

Crucell is a biotechnology company based in Leiden, The Netherlands, that develops vaccines and antibodies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.